Hello, Fool! | Login | Signup | My Fool
Oct 11, 2008 5:58 PM ET | Feedback | Site Changes | Help
A biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.
View All Commentary (RPRX)
Recs
zzlangerhans (98.66) Submitted: 8/15/07 9:23 PM : Start Price: $12.68 RPRX Score: -11.27
Androxal and Proellex are likely 2008 NDA submissions. Coverage from unbiased sources is very thin, and there are potential problems with cytopathologic endometrial changes with Proellex. However, despite price near 13 market cap is only 165M which improves the risk/benefit profile substantially.
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.